Media headlines about Momenta Pharmaceuticals (NASDAQ:MNTA) have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.5704719193529 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s analysis:
- Stocks To Watch: Momenta Pharmaceuticals Sees Relative Strength Rating Jump To 85 (investors.com)
- Momenta Pharmaceuticals (MNTA) Rating Lowered to Hold at BidaskClub (americanbankingnews.com)
- Momenta Pharmaceuticals (MNTA) Downgraded by BidaskClub (americanbankingnews.com)
- Momenta Pharmaceuticals Stock (profitconfidential.com)
- Momenta Pharmaceuticals Stock Is on the Verge of Breaking Out (jutiagroup.com)
Shares of NASDAQ:MNTA traded up $0.35 during mid-day trading on Thursday, hitting $18.15. The stock had a trading volume of 857,489 shares, compared to its average volume of 916,325. The firm has a market cap of $1,325.81, a price-to-earnings ratio of -14.88 and a beta of 1.72. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.25.
MNTA has been the topic of several recent analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $18.00 price objective on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $15.33.
In related news, CEO Craig A. Wheeler sold 3,938 shares of Momenta Pharmaceuticals stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $16.46, for a total value of $64,819.48. Following the transaction, the chief executive officer now directly owns 239,869 shares in the company, valued at approximately $3,948,243.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Craig A. Wheeler sold 35,666 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total value of $503,247.26. The disclosure for this sale can be found here. Insiders sold a total of 106,502 shares of company stock worth $1,661,696 in the last three months. Company insiders own 4.40% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.